Minerva Neurosciences Inc
NERV1.940USD
+0.027+1.44%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
13.57MMarktkapitalisierung
2.17KGV TTM
mehr Informationen über Minerva Neurosciences Inc Unternehmen
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.
Unternehmensinformationen
BörsenkürzelNERV
Name des UnternehmensMinerva Neurosciences Inc
IPO-datumJun 25, 2014
CEODr. Remy Luthringer, Ph.D.
Anzahl der mitarbeiter8
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse1601 Trapelo Road
StadtWALTHAM
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02451
Telefon16176007373
Websitehttps://www.minervaneurosciences.com/
BörsenkürzelNERV
IPO-datumJun 25, 2014
CEODr. Remy Luthringer, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Remy Luthringer, Ph.D.
Dr. Remy Luthringer, Ph.D.
Executive Chairman of the Board of Directors, Chief Executive Officer
Executive Chairman of the Board of Directors, Chief Executive Officer
184.82K
--
Mr. Geoffrey Race
Mr. Geoffrey Race
President
President
51.32K
--
Dr. David J. Kupfer, M.D.
Dr. David J. Kupfer, M.D.
Independent Director
Independent Director
23.94K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
1.25K
--
Dr. Fouzia Laghrissi-Thode, M.D.
Dr. Fouzia Laghrissi-Thode, M.D.
Independent Director
Independent Director
--
--
Mr. Jan G. Van Heek
Mr. Jan G. Van Heek
Independent Director
Independent Director
--
--
Mr. Frederick Ahlholm, CPA
Mr. Frederick Ahlholm, CPA
Chief Financial Officer, Senior Vice President, Secretary
Chief Financial Officer, Senior Vice President, Secretary
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Remy Luthringer, Ph.D.
Dr. Remy Luthringer, Ph.D.
Executive Chairman of the Board of Directors, Chief Executive Officer
Executive Chairman of the Board of Directors, Chief Executive Officer
184.82K
--
Mr. Geoffrey Race
Mr. Geoffrey Race
President
President
51.32K
--
Dr. David J. Kupfer, M.D.
Dr. David J. Kupfer, M.D.
Independent Director
Independent Director
23.94K
--
Mr. Hans Peter Hasler
Mr. Hans Peter Hasler
Independent Director
Independent Director
1.25K
--
Dr. Fouzia Laghrissi-Thode, M.D.
Dr. Fouzia Laghrissi-Thode, M.D.
Independent Director
Independent Director
--
--
Mr. Jan G. Van Heek
Mr. Jan G. Van Heek
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2021
FY2020
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Federated Hermes Global Investment Management Corp.
19.32%
Boehringer Ingelheim International GmbH
18.23%
The Vanguard Group, Inc.
3.60%
Luthringer (Remy)
2.64%
Renaissance Technologies LLC
1.63%
Other
54.57%
Aktionäre
Aktionäre
Anteil
Federated Hermes Global Investment Management Corp.
19.32%
Boehringer Ingelheim International GmbH
18.23%
The Vanguard Group, Inc.
3.60%
Luthringer (Remy)
2.64%
Renaissance Technologies LLC
1.63%
Other
54.57%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
24.51%
Corporation
18.23%
Individual Investor
4.02%
Hedge Fund
1.85%
Investment Advisor
1.64%
Research Firm
0.11%
Other
49.64%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
48
3.52M
50.36%
-225.80K
2025Q1
50
3.52M
50.36%
-205.49K
2024Q4
51
3.66M
52.27%
-624.23K
2024Q3
54
3.69M
57.40%
+418.43K
2024Q2
57
3.64M
56.76%
+303.74K
2024Q1
68
3.68M
57.33%
+358.05K
2023Q4
70
4.01M
62.11%
+650.59K
2023Q3
86
4.01M
62.11%
+311.12K
2023Q2
109
3.95M
71.07%
+754.34K
2023Q1
139
1.91M
35.70%
-1.35M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Federated Hermes Global Investment Management Corp.
1.35M
19.32%
--
--
Mar 31, 2025
Boehringer Ingelheim International GmbH
1.27M
18.23%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
252.06K
3.6%
--
--
Mar 31, 2025
Luthringer (Remy)
184.82K
2.64%
--
--
Mar 31, 2025
Renaissance Technologies LLC
114.10K
1.63%
-14.00K
-10.93%
Mar 31, 2025
Geode Capital Management, L.L.C.
76.73K
1.1%
+20.28K
+35.91%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
72.67K
1.04%
--
--
Mar 31, 2025
Race (Geoffrey)
51.32K
0.73%
--
--
Mar 31, 2025
Kupfer (David J)
23.94K
0.34%
--
--
Mar 31, 2025
Apella Wealth
20.63K
0.29%
+20.63K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
Datum
Art
Verhältnis
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
Jun 17, 2022
Merger
8<1
